The Potency of Mesenchymal Stem Cells as Viral Oncolytic Carriers

Oncolytic viruses (OVs) represent a category of viruses that selectively replicate within tumor cells, destroying cancer cells through a dual mechanism involving viral oncolysis and the stimulation of the host's anti-tumor immune response. This selectivity ensures the virus targets and eliminates cancer cells while sparing healthy cells. Oncolytic virus immunotherapy refers to treatments utilizing either native or genetically modified OVs designed to replicate within tumor cells selectively. Mesenchymal Stem Cells (MSCs) have demonstrated potential in facilitating the safe transportation and targeted release of oncolytic viruses at the tumor site due to their inherent tumor-specific homing capability. Utilizing MSCs as carriers for oncolytic viruses can enhance the delivery of these therapeutic agents to the tumor site, eliminating the need for direct tumor injection and reducing the associated side effects.

Authors

Institutions

Publication Details

Journal
Clinical and Research Journal in Internal Medicine
Published
2024-11-25
DOI
https://doi.org/10.21776/ub.crjim.2024.005.02.10
Primary Topic
Virus-based gene therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Potency of Mesenchymal Stem Cells as Viral Oncolytic Carriers

Muhammad Farid Rakhman
Clinical and Research Journal in Internal Medicine
Virus-based gene therapy research
article

The Potency of Mesenchymal Stem Cells as Viral Oncolytic Carriers

Muhammad Farid Rakhman
article en

Abstract

Oncolytic viruses (OVs) represent a category of viruses that selectively replicate within tumor cells, destroying cancer cells through a dual mechanism involving viral oncolysis and the stimulation of the host's anti-tumor immune response. This selectivity ensures the virus targets and eliminates cancer cells while sparing healthy cells. Oncolytic virus immunotherapy refers to treatments utilizing either native or genetically modified OVs designed to replicate within tumor cells selectively. Mesenchymal Stem Cells (MSCs) have demonstrated potential in facilitating the safe transportation and targeted release of oncolytic viruses at the tumor site due to their inherent tumor-specific homing capability. Utilizing MSCs as carriers for oncolytic viruses can enhance the delivery of these therapeutic agents to the tumor site, eliminating the need for direct tumor injection and reducing the associated side effects.

Clinical and Research Journal in Internal MedicineVol. 5(2)
Lampung University (ID)
Openalex Percentile: Top 76%
Virus-based gene therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.